Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Improving Lupus Drug Regimen Adherence Among Minorities

Michael Putman, MD  |  Issue: February 2022  |  February 10, 2022

Improving Adherence

Dr. Sun and her colleagues developed an individualized intervention to help university lupus clinic providers better recognize and address nonadherence. Providers and patients examine pharmacy data on how often patients pick up prescriptions. The providers give positive reinforcement to patients who pick up at least 80% of prescriptions. If there are gaps in refills, the providers ask openended questions about the reasons and try to identify and address each patient’s barriers.

In a 12-week pilot involving 134 patients, the researchers compared adherence rates from three months before the intervention to three months after it. Adherence increased from 11% for hydroxychloroquine, 12% for disease-modifying anti-rheumatic drugs and 9% for mycophenolate mofetil. Among 48 patients who completed surveys, no patient reported feeling angry, upset or embarrassed.3 “We’re trying to improve this intervention,” Dr. Sun says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

She notes tactics others can use, like asking open-ended questions about adherence barriers in ways that validate patient experience. “For example, you can say it’s common to miss doses because many people have trouble remembering, paying for the medications or not understanding what they are for. Then ask, ‘Are those ever an issue for you?’”

Have a list of resources patients can use to help overcome particular barriers, such as contact information for social workers who can help with insurance problems. Recommend applications that help with busyness or forgetting doses.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Build trusting relationships with patients by empathizing with them, Dr. Sun adds. Although her study did not examine systemic racism or providers’ implicit bias, she believes these may sometimes play a role in poor medication adherence.4

“Let’s look at how we’re handling clinic encounters with minority patients,” Dr. Sun says. “Equality means everyone gets the same thing, but equity is giving everyone the same opportunity to achieve the same outcomes.”

Deborah Levenson is a writer and editor based in College Park, Md.

References

  1. Sun K, Corneli AL, Dombeck C, et al. Barriers to taking medications for systemic lupus erythematosus: A qualitative study of racial minority patients, lupus providers, and clinic staff. Arthritis Care Res (Hoboken). 2021 Mar 4;10.1002/acr.24591.
  2. Sun K, Eudy AM, Criscione-Schreiber LG, et al. Racial disparities in medication adherence between African American and Caucasian patients with systemic lupus erythematosus and their associated factors. ACR Open Rheumatol. 2020 Jul;2(7):430–437.
  3. Sun K, Rogers J, Sadun R, et al. Intervention to improve SLE medication adherence using Surescripts pharmacy refill data [abstract]. Arthritis Rheumatol. 2020;72(suppl 10).
  4. Peckham C. Medscape rheumatologist lifestyle report 2017: Race and ethnicity, bias and burnout. 2017 Jan. 11. https://www.medscape.com/features/slideshow/lifestyle/2017/rheumatology#page=1.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:adherenceDisparities

Related Articles

    Medication Non-Adherence by Rheumatology Patients & What Rheumatologists Can Do

    April 1, 2015

    Lack of efficacy, poor DAS scores may be misinterpreted as a drug failure

    New Study Probes Hydroxychloroquine Adherence During Pregnancy

    May 11, 2023

    Hydroxychloroquine (HCQ) is nearly universally recommended for pregnant patients with systemic lupus erythematosus (SLE) to reduce lupus disease activity and adverse outcomes in pregnancy.1-3 Yet despite strong evidence supporting its benefits, HCQ appears underutilized, with several studies suggesting fewer than half of all women with lupus take this medication during pregnancy.4 How accurately these results…

    Break Barriers: Engaging Diverse Participants in Clinical Trials for Patients with Lupus

    September 14, 2023

    Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.

    When to Check Drug Levels & Why

    March 7, 2024

    Checking blood levels of commonly used disease-modifying anti-rheumatic drugs (DMARDs) has gained widespread attention in the rheumatology community, even resulting in a recent guidance document from EULAR for biologics.1 Although a highly useful tool, drug level measurement in rheumatology is not without challenges; many of our drugs violate the basic principles of pharmacology that we…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences